Q4 2025 Agios Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Agios Pharmaceuticals Inc (AGIO) successfully launched AQVESME for the treatment of thalassemia in the US, with strong early demand and 44 prescriptions written by REMS-certified physicians.
- The company reported robust financial performance with PYRUKYND delivering $20 million in net revenue in Q4, contributing to a full-year revenue of $54 million, reflecting significant year-on-year growth.
- Agios Pharmaceuticals Inc (AGIO) ended 2025 with approximately $1.2 billion in cash, providing financial flexibility to support ongoing and future initiatives.
- The company has a clear path to profitability through its existing commercial presence in thalassemia and PK deficiency, with disciplined capital allocation and operational efficiency.
- Agios Pharmaceuticals Inc (AGIO) is advancing its pipeline with promising developments, including the completion of enrollment in the phase 2 sickle cell disease trial of tebapivat and anticipated topline results in 2026.
- The conversion from prescription to treatment initiation for AQVESME is expected to take 10 to 12 weeks, potentially delaying revenue recognition.
- Agios Pharmaceuticals Inc (AGIO) anticipates a sequential decline in ex-US revenues in Q1 2026 due to inventory stocking ahead of demand in Europe.
- R&D expenses increased to $88.1 million in Q4 2025, reflecting higher costs associated with advancing early-stage pipeline programs.
- The company faces challenges in navigating the regulatory path for mitapivat in sickle cell disease, with outcomes from the Pre-sNDA meeting still pending.
- Agios Pharmaceuticals Inc (AGIO) must manage potential bottlenecks in the AQVESME REMS certification process, which could impact the pace of treatment initiation.
Good morning and welcome to Agios Pharmaceuticals fourth quarter in full year 2025 conference call. (Operator Instructions). Please be advised that this call is being recorded at Agio's request. I would now like to turn the call over to Morgan Sanford, Head of Investor Relations at Agios. Please go ahead.
Thank you, operator. Good morning, everyone. Thank you for joining us to discuss Agios Pharmaceuticals fourth quarter and full year 2025 financial results and business highlights. You can access the slides for today's call by going to the Investors section of our website agios.com.
Please note we'll be making certain forward-looking statements today. Actual events and results could differ materially from those expressed or implied by any forward-looking statements because of various risks, uncertainties, and other factors, including those set forth in our most recent filings with the SEC and any other future filings that we may make with the SEC.
On the call with me today
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
